Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection
Status:
Completed
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
This clinical study will evaluate whether grazoprevir and elbasvir is efficacious, safe, and
well-tolerated in peginterferon alfa plus ribavirin experienced patients who inject drugs
(PWID) and men who sex with men (MSM) with genotype 1 HCV and HIV co-infection.